Biotech Values

[DewDiligence]

Samsung says its FoB’s will be priced at about half the prevailing prices of the corresponding branded drugs in developed markets:

http://www.ft.com/intl/cms/s/0/8d0f2320-86ed-11e1-ad68-00144feab49a.html

Samsung does not specify the geographies in which the purported 50% “discount” will apply, so this information is not especially useful for market-calibration purposes. Still, I thought it was worth mentioning insofar as it’s the first prediction of such a steep discount I’ve seen from one of the prospective participants in the FoB arena.

Sansung inked an FoB partnership with BIIB in Dec 2011 (#msg-69629103). The joint venture is called Samsung Bioepis (#msg-72636262).